BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Levetiracetam (Keppra) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Levetiracetam (Keppra)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06866691-7060@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Levetiracetam (Keppra): Phase 4 readout est. (NCT06866691)
DESCRIPTION:Levetiracetam (Keppra)\, phase 4.\nStudy: Seizure Prevention in
  Traumatic Brain Injury With Levetiracetam and Lacosamide\nEstimated prima
 ry completion: April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/levetiracetam-keppra#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06866691
URL:https://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01666080-7060@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Levetiracetam (Keppra): Phase na readout est. (NCT01666080)
DESCRIPTION:Levetiracetam (Keppra)\, phase na.\nStudy: Second or Greater Al
 logeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Condit
 ioning (RIC)\nEstimated primary completion: June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT01666080
URL:https://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735717-7060@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Levetiracetam (Keppra): Phase 2 readout est. (NCT05735717)
DESCRIPTION:Levetiracetam (Keppra)\, phase 2.\nStudy: MT2021-08T Cell Recep
 tor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies\nEstim
 ated primary completion: 30 November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05735717
URL:https://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03048084-7060@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Levetiracetam (Keppra): Phase 4 readout est. (NCT03048084)
DESCRIPTION:Levetiracetam (Keppra)\, phase 4.\nStudy: Seizure Treatment in 
 Glioma\nEstimated primary completion: 1 January 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03048084
URL:https://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130786-7060@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Levetiracetam (Keppra): Phase 2 readout est. (NCT07130786)
DESCRIPTION:Levetiracetam (Keppra)\, phase 2\, Epilepsy.\nStudy: Prophylact
 ic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With
  Primary Motor Cortex Brain Metastases\nEstimated primary completion: Febr
 uary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/levetirace
 tam-keppra#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07130786
URL:https://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220902-7060@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Levetiracetam (Keppra): Phase 3 readout est. (NCT07220902)
DESCRIPTION:Levetiracetam (Keppra)\, phase 3.\nStudy: Levetiracetam Compare
 d to Magnesium Sulfate for Prevention of Eclamptic Seizure\nEstimated prim
 ary completion: 31 December 2033. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/levetiracetam-keppra#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07220902
URL:https://assetmemo.bio/drug/levetiracetam-keppra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
